Trial Profile
A study in renal predialysis and dialysis patients of the safety, tolerability, and immunogenicity of recombinant hepatitis B vaccine manufactured with a modified process
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Hepatitis B vaccine recombinant (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Merck & Co; Merck Sharp & Dohme
- 16 May 2019 This trial has been completed in Spain as per European Clinical Trials Database record.
- 29 Oct 2009 Results were presented at IDSA 2009.
- 03 Nov 2008 Trial identifier amended as reported by ClinicalTrials.gov.